V
Vertero Therapeutics
Clinical-stage CNS bio-pharmaceutical company focused on small molecule therapies
About Vertero Therapeutics
Axial Therapeutics, a clinical-stage biopharmaceutical company, was established in 2016 to concentrate on the connection between the human gut microbiome and neurological diseases. The company's scientific foundation is built upon the research of its co-founder, Dr. Sarkis Mazmanian, a professor at the California Institute of Technology (Caltech) whose work has explored the gut-brain axis and its implications for central nervous system (CNS) disorders. Dr. Mazmanian's extensive background in microbiology and immunology, particularly his research into how gut bacteria can influence health and disease, provides the scientific underpinning for the company's therapeutic approach.
Axial Therapeutics is developing a pipeline of small molecule therapies designed to address the neurological symptoms of conditions like Parkinson's disease (PD) and Autism Spectrum Disorder (ASD). The company's strategy focuses on identifying and targeting specific bacterial metabolites originating in the gut that are believed to contribute to disease pathology. Rather than using live biotherapeutics, Axial's approach is to develop orally-administered small molecules that can remove these harmful metabolites from the gut before they enter the bloodstream and impact the brain. This business model is centered on the traditional biopharmaceutical pathway of drug discovery, clinical development, and eventual commercialization of approved therapies. Its primary clients are patients suffering from these neurological disorders, with the products intended to be prescribed by healthcare professionals.
The company's lead product candidate, AB-2004, is a gut-targeted, molecular therapy being investigated for its potential to reduce irritability and anxiety in children with Autism Spectrum Disorder. AB-2004 is designed to selectively absorb certain gut-derived metabolites that are thought to cross the blood-brain barrier and affect brain function. The key differentiator for this product is its focus on the gastrointestinal system to treat neurological symptoms, potentially offering a safer profile by minimizing systemic exposure. In 2022, Axial completed a Phase 2b clinical trial for AB-2004 in adolescents with ASD. Another significant milestone was the completion of a Series C financing round in 2021, which raised $37.25 million to advance its clinical programs for both ASD and Parkinson's disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 88.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Drug Development, Neurology, Microbiome, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Vertero Therapeutics is 670 monthly website visits, down 66.5% over the last three months. Vertero Therapeutics's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vertero Therapeutics in the Woburn ecosystem
The Vertero Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Longwood Fund
Domain Associates
Kairos Ventures
Seventure Partners- TVTaiho Ventures
Series B and later5 investors entered at this stage
UTokyo Innovation Platform
One Ventures
Corundum Systems Biology
Taiho Pharma- AFAutism Impact Fund
Other known investors1 additional known investor
Caltech, California Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vertero Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vertero Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










